ArticleJournal of clinical & translational endocrinology2025
Urinary DcR2/Cr level predicts renal outcomes in patients with diabetic kidney disease.
Article in Journal of clinical & translational endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tubular Injury in Diabetic Kidney Disease: Early Diagnosis and Intervention Strategies.Diabetes/metabolism research and reviews · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In diabetic kidney disease (DKD), urinary decoy receptor 2 (uDcR2) levels are associated with tubulointerstitial fibrosis; however, whether uDcR2 can predict renal outcomes remains unclear. Herein, we analyzed the association between uDcR2 and renal outcomes (defined as a composite of a serum creatinine (SCr) increase of 50 % from baseline, or initiation of dialysis for end-stage renal disease) in 153 patients with biopsy-proven DKD. Patients were divided into the composite (n = 67) and no composite (n = 86) outcome groups. uDcR2 levels were measured using ELISA. The area under the receiver operating characteristic curve (AUC) for uDcR2 in discriminating DKD renal outcomes was calculated. Kaplan-Meier survival analysis and multifactorial Cox regression models evaluated the association between uDcR2 levels and renal outcomes. Renal DcR2 mRNA and protein expression were detected using in situ hybridization and immunohistochemical staining. Immunofluorescence revealed DcR2 and α-SMA colocalization. uDcR2/Cr levels were higher in patients in the composite than the no composite outcome group. uDcR2/Cr levels positively correlated with ACR, SCr, interstitial fibrosis and tubular atrophy (IFTA), and negatively correlated with eGFR. uDcR2/Cr had an AUC of 0.825 at the optimal cut-off value of 389 ng/gCr. Addition of uDcR2/Cr to ACR, eGFR, or IFTA improved renal outcome predictions. Renal survival was significantly lower at uDcR2/Cr ≥ 389 ng/gCr. Patients in the composite group had higher tubular DcR2 mRNA and protein level percentages. α-SMA was significantly increased in DcR2-positive renal tubules and their surroundings. Overall, uDcR2/Cr is an independent predictor of renal outcomes, with potential for improving the prevention and treatment of DKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.